Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NBIP-1968
- Development stage
- Preclinical
- Lead developer
- Neurocrine Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NBIP-1968 is an investigational, internally discovered small molecule triple agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Developed by Neurocrine Biosciences, it is designed for the treatment of obesity and other metabolic disorders. As a small molecule, it is intended for oral administration, offering a potential alternative to injectable peptide-based incretin therapies. Neurocrine is exploring its use both as a monotherapy and in combination with NBIP-2118, a CRF2 receptor agonist, to maximize weight loss and metabolic benefits.
02
Targets
Beyond the preview
Go deeper on NBIP-1968.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NBIP-1968.